Oncometabolites Analysis Service

What is Oncometabolites Analysis and Why It Matters?

Oncometabolites Analysis is a specialized Targeted Metabolomics approach designed to quantify specific metabolites that accumulate to supraphysiological levels due to cancer-associated mutations (e.g., IDH1/2, SDH, FH) or enzyme dysregulation.

Unlike general metabolic profiling, this service focuses on absolute quantification and chiral separation of molecules that directly drive tumorigenesis, epigenetic remodeling, and immune suppression. It is the gold standard for confirming whether a genetic mutation (e.g., IDH1 R132H) translates into a functional metabolic phenotype (e.g., D-2-HG production).

Overcoming Key Challenges in Cancer Metabolism Research

Resolving Isomer Ambiguity (D- vs L-2-HG)

Challenge: Standard LC-MS methods cannot distinguish oncogenic D-2-HG (from IDH mutations) from L-2-HG (produced under hypoxia/acidosis), leading to false positives.

Solution: We employ validated chiral chromatography to achieve baseline separation of enantiomers, ensuring your data reflects true mutation status, not just hypoxic stress.

Capturing Labile Pathway Intermediates

Challenge: Critical TCA intermediates like Succinate, Fumarate, and Oxaloacetate turn over rapidly and degrade within seconds of sampling.

Solution: Our protocol includes optimized quenching steps and cold-chain extraction with isotope-labeled internal standards to "freeze" the metabolic state instantly.

Profiling the Heterogeneous TME

Challenge: Tumors are spatially heterogeneous; obtaining signal from necrotic cores or interstitial fluid is technically demanding.

Solution: We offer high-sensitivity assays validated for complex matrices, including 3D spheroids, organoids, and scarce Tumor Interstitial Fluid (TIF).

Service Scope: Targeted Quantification and Optional Flux Analysis

We provide a modular workflow aligned to your study stage, sample type, and pathway hypothesis:

• Targeted Oncometabolite Quantification: Absolute or relative quantification for selected targets (e.g., 2-HG, lactate/pyruvate, TCA intermediates) using calibration curves with internal standards (target-dependent).
• Chiral 2-HG Resolution Assay: Dedicated chiral LC–MS/MS workflow to quantify D-2-HG and L-2-HG and report the D/L balance.
• Optional Metabolic Flux Analysis (MFA): Add ¹³C-glucose or ¹³C-glutamine tracing and quantify mass isotopologue distributions (MID) to support pathway activity interpretation (see Metabolic Flux Analysis Service).
• Tumor Microenvironment (TME) Metabolic Nodes: Quantify key TME-relevant nodes, including nutrient utilization (e.g., glucose/glutamine) and secretion readouts (e.g., lactate/pyruvate). Kynurenine/tryptophan modules are available as optional add-ons.

Analyte Coverage: Core Oncometabolites and Central Carbon Nodes

Our panel covers core cancer-relevant metabolites, with optional pathway and cofactor add-ons depending on study design and extraction requirements.

*Note: Final target list is confirmed at project setup and reported in the methods appendix.

Why Choose Our Oncometabolites Profiling Service?

• True Chiral Precision: We don't just measure "Total 2-HG." We separate D- and L-forms to confirm IDH mutation status versus general hypoxic response, a distinction critical for high-impact publications.
• Absolute Quantification Standard: We utilize isotope-labeled internal standards (e.g., ¹³C₅-2-HG, ¹³C₄-Succinate) for every class, providing concrete concentration data (e.g., μM or ng/mg) rather than relative peak areas.
• Broad Dynamic Range: Our methods are optimized to quantify metabolites across 4-5 orders of magnitude, accurately measuring both trace intracellular signals and high-abundance media nutrients in a single run.
• Flux-Ready Platform: Our methods are inherently compatible with stable isotope tracers. You can upgrade any study from "static pool size" to "dynamic flux" without changing the core analytical platform.

Project Workflow: Step-by-Step Analysis

1

Study Consultation

Define targets (e.g., IDH, Warburg), sample types, and whether flux labeling is required.

2

Sample Collection

Guidance on standardized quenching protocols (e.g., liquid N2 flash freezing) to preserve unstable metabolites.

3

Metabolite Extraction

Optimized cold organic extraction spiked with isotope-labeled internal standards to correct for recovery losses.

4

LC-MS/MS Acquisition

Targeted quantitation is performed via LC–MRM on Sciex QTRAP platforms, with optional high-resolution accurate-mass confirmation and isotopologue analysis on Thermo Orbitrap systems.

5

Data Processing

Rigorous peak integration, chiral resolution verification, and quantification calculation.

6

Comprehensive Reporting

Final report includes standard curves, QC performance data, and biological visualization plots.

Stepwise oncometabolite workflow from study design and quenching to isotope-dilution LC–MS/MS, data processing, and reporting.

Analytical Platforms & Quality Control Standards

We utilize industry-leading instrumentation to ensure data integrity and reproducibility.

Instrumentation:

• Sciex QTRAP 6500+: Selected for its unmatched sensitivity in targeted quantitation (MRM mode), ideal for low-abundance oncometabolites.
• Thermo Orbitrap Exploris 480: Used for high-resolution confirmation and complex flux analysis (mass isotopologue distribution).

Quality Control Specs:

• Linearity: Calibration curves with R2 ≥ 0.99 for all quantified analytes.
• Precision: Technical replicate RSD < 15% for quality control samples.
• Carryover: Strict blank monitoring between samples to prevent cross-contamination.

Sample Types & Submission Requirements

Packaging checklist: Dry ice in an insulated container; sample inventory sheet; clearly labeled tubes; secondary containment to prevent leakage.

Deliverables: Publication-Ready Data Package

We provide a comprehensive data package designed for direct inclusion in manuscripts.

Data Report:

• Concentration tables (Excel/CSV).
• Calibration curve parameters and QC performance report.

Representative Data Visualization:

• Chiral 2-HG Chromatogram: Baseline separation of D- and L-2-Hydroxyglutarate.
• Differential Volcano Plot: Identifying significant metabolic shifts in mutant tumors.
• TCA Cycle Heatmap: Visualizing metabolic bottlenecks in the TCA cycle.
• Drug Response Bar Chart: Assessing drug efficacy on oncometabolite levels.

(Need advanced data interpretation? See our Metabolomics Data Analysis services).

Chiral LC–MS/MS resolves D-2-HG from L-2-HG, enabling confident IDH-associated oncometabolite readouts.

Isotope-dilution LC–MS/MS delivers absolute quantification with linear calibration, tight precision, and carryover control.

Central carbon profiling reveals mutation-linked TCA signatures, capturing succinate/fumarate shifts and glycolysis nodes.

13C-glucose tracing MID reports pathway activity, linking glycolysis-to-TCA carbon flow with flux-ready evidence.

Applications in Oncology Research